Mike: Because the last stock I was in before AMBS rocketed after it started bringing in revenue on a new drug, I am very bullish on what will happen to our stock price after January when Lympro starts bringing in revenue. For some reason, I don't feel at all worried about this, and yes and I would be willing to buy shares on margin. (Especially, if we up list after being only at .30 cents or less.)

When it comes to MANF and everything else we have - I'm excited, but have no idea when they will cause our stock price to pop. MANF is still pre-clinical. I think the orphan designations will help us, but I really don't know how to quantify that. Starting an Eltoprazine phase 2b trial will help us, but I don't know how to quantify that, either. Same with Phenoguard. I'm very glad we have these therapeutic drugs in our pipeline, but I don't know when they will add significant shareholder value.